1Lusuardi M. Role of surfactant in chronic obstructive pulmonary disease; therapeutic implications[ J ]. Respiration,1992, 59 (Suppl) 1: 28～ 32
2Gillissen A Characterization of N - acetylcysteine qnd ambroxolin anti - oxedant therapy[J ]. Respir Med, 1998, 92(4):609～23
3Houtmeyers E. Effects of drugs on mucus clearance[J ].Eur Respir J, 1999, 14(2):452-467
4Uchida M. Effects of ambroxol HCL on the guinea pig tracheal mucous secretion qnd the rat pulmonary surfactant secretion [ J ]. Nippon - Yakurigaku - Zasshi, 1992,100(4): 293 ～ 300
5Derelle J. Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus cornase alfa[J].Arch Pediatr, 1998, 5(4): 371 ～ 377
6Nowad D. Antioxidant properties of Ambroxol [ J ]. Free Radio Biol Med, 1994, 16(4):517-22
7Zwadlo K. larwasser- G. Ambroxol inhibits histamine release from human adenoidal mast cell[J ]. Inflamm- Res,1998, 47 Suppl 1 :S16 ～ 17
8Lusuardi M,Cape 1 li A,Carli S,etal.Role of surfactant in chronic obst ructive pulmonary disease:therapeuticimplications.Respiration,1992,59(Suppl 1): 28-32.
9Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol inanti-oxedant therapy.Respir Med,1998,92(4):609-623.
10Houtmeyers E.Effects of drugs on mucus clearance.Eur Respir J,1999,1 4(2):452-467.
